The study and its comparison
Sixty-seven hemodialysis patients with subjective sleep problems were randomized to melatonin or placebo for twelve months. Forty-two completed the trial. Quality-of-life vitality was the primary endpoint. [1]
Vitality did not improve. At three months, sleep efficiency and sleep time on dialysis days favored melatonin; by twelve months, none of the measured sleep parameters differed significantly from placebo. [1]
What the finding establishes
Short-term improvement should not be described as lasting benefit. Substantial dropout weakens the conclusions, and mixed secondary quality-of-life findings need caution. The trial measured sleep and vitality, not kidney recovery. Funding and complete conflicts were not established from the abstract. Results in dialysis patients do not define use in every kidney condition. [1]
A hypothetical distinction
Imagine an improvement appears at three months but is absent at twelve. A one-year benefit claim would hide the time course.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Long-term effects of melatonin on quality of life and sleep in haemodialysis patients (Melody study): a randomized controlled trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.